Late-stage TED Viridian is advancing two global Phase 3 trials for thyroid eye disease (TED) with VRDN-001 and a plan to add VRDN-003 for SC administration, signaling potential near-term commercialization opportunities and need for payer and patient access dialogues.

Launch Momentum Lumvoa received FDA approval and recent market launch, supported by a patient-focused program ViridianCares, creating immediate upsell and channel opportunities with ophthalmology and autoimmune disease clinics seeking new therapeutic options and patient support.

Strategic Partnerships WuXi Biologics manufacturing collaboration highlights an emphasis on scalable production and supply stability, offering BD avenues in contract manufacturing, global supply chain planning, and risk-sharing manufacturing discussions for potential CDMOs or strategic investors.

FcRn/TSHR Portfolio Beyond TED, Viridian’s FcRn inhibitors and anti-TSHR programs indicate a broader autoimmune pipeline, presenting cross-sell potential to contract research organizations, specialty pharmacies, and patients with related conditions like Graves’ disease.

Financial Upside With a substantial funding runway and a $251M public offering completed, there is financial flexibility to pursue strategic collaborations, co-development deals, or licensing in adjacent rare disease indications, aligning with partners seeking late-stage assets and risk-sharing structures.